|
1）Ghofrani HA, Grimminger F. Modulating cGMP to treat lung diseases. Handb Exp Pharmacol. 2009; 191: 469-83
|
|
|
|
2）循環器病の診断と治療に関するガイドライン（2011年度合同研究班報告）肺高血圧症治療ガイドライン（2012 年改訂版）日本循環器学会ホームページ；http://www.j-circ.or.jp/guideline/pdf/JCS2006_nakano_h.pdf
|
|
|
|
|
|
3） Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013; 62: D13-21
|
|
|
|
|
4） Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002; 165: 800-4
|
|
|
|
|
|
5） Minai OA, Parambil J, Dweik RA, et al. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Respir Med. 2013; 107: 458-65
|
|
|
|
|
|
6）Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007; 132: 757-63
|
|
|
|
|
|
7）Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347: 322-9
|
|
|
|
|
|
8）Morrison K, Studer R, Ernst R, et al. Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther. 2012; 343: 547-55
|
|
|
|
|
|
9） Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012; 40: 874-80
|
|
|
|
|
|
10） Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369: 809-18
|
|
|
|
|
|
11）Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369: 330-40
|
|
|
|
|
|
12）Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013; 369: 319-29
|
|
|
|
|
|
13） Chen YF, Jowett S, Barton P, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary hypertension within their licenced indications: a systematic review and economic evaluation. Health Technol Assess. 2009; 13: 1-320
|
|
|
|
|